Clinical Trials Logo

CML, Refractory clinical trials

View clinical trials related to CML, Refractory.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03884829 Recruiting - Clinical trials for Myelodysplastic Syndromes

A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

Start date: March 25, 2019
Phase: Phase 1
Study type: Interventional

A Phase I Pharmacologic Study of CYC140, a polo-like kinase 1 inhibitor, in Patients with Advanced Leukemias or Myelodysplastic Syndromes

NCT ID: NCT03459534 Recruiting - Clinical trials for Chronic Myeloid Leukemia, Chronic Phase

A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

Start date: June 25, 2018
Phase: Phase 3
Study type: Interventional

In a multinational, multicenter, single-arm, open-label and Phase III Radotinib clinical study, chronic phase Ph+ chronic myeloid leukemia patients with failure or intolerance to previous TKIs therapy including Imatinib will be recruited. In this phase 3 study, 173 subjects are expected to be enrolled in a single arm with the administration of Radotinib 400mg twice daily, which includes 10% of dropout rate.